140 results
S-3ASR
EX-5.1
ADAP
Adaptimmune Therapeutics Plc
10 Aug 20
Automatic shelf registration
5:01pm
and Company, LLC (the "Sales Agreement").
For the purpose of this letter Ordinary Shares and Warrants are collectively referred to as "Equity Securities … office, 201 Bishopsgate, London EC2M 3AF, England or on www.mayerbrown.com.
Examination and enquiries
For the purpose of giving this opinion, we
S-8
ADAP
Adaptimmune Therapeutics Plc
30 Aug 19
Registration of securities for employees
12:30pm
. dollars based on a conversion rate of £1=$1.2242.
Calculated solely for the purpose of determining the registration fee pursuant to the provisions … of options previously granted under Adaptimmune Therapeutics plc 2015 Share Option Scheme.
Calculated solely for the purpose of determining
S-8
ADAP
Adaptimmune Therapeutics Plc
30 Nov 23
Registration of securities for employees
4:16pm
for the purpose of calculating the registration fee pursuant to Rule 457(h) under the Securities Act on the basis of $0.5116, which is the weighted average … upon exercise of options to be granted pursuant to and in accordance with the Plans.
Computed solely for the purpose of calculating the registration
F-6EF
EX-99
ADAP
Adaptimmune Therapeutics Plc
30 Aug 19
Automatic registration for ADRs (foreign)
1:06pm
by the Deposit Agreement (as hereinafter defined) for the purpose of registering under the United States Securities Act of 1933, as amended … and interpretative advice). Without admitting that anything contained herein or in any document referred to herein constitutes “tax advice” for any purpose
8-K
EX-10.1
swjzw19w786q8c1k
18 Feb 20
Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer
8:07am
8-K
EX-10.1
vpgho
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
S-3ASR
EX-5.1
1cjlt8dhjh xsqhwiah
12 Jul 18
Automatic shelf registration
4:30pm
6-K
EX-99.1
v5yu5n4hm0
9 Oct 15
Adaptimmune announces New Research and Development Facility in Oxfordshire
12:00am
10-K
EX-10.17
x817jwm30d601
13 Mar 17
Annual report
12:00am
8-K
EX-10.1
s7fjict
20 Dec 22
Entry into a Material Definitive Agreement
4:05pm
DRS
EX-10.3
aw0i4sbps 3tb9gm
5 Feb 15
Draft registration statement
12:00am
8-K
EX-14.1
qctmqwnlpvzn ewsr60
24 Jul 17
Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
12:00am
20-F
EX-4.13
rzly 30of3gfdh
13 Oct 15
Annual report (foreign)
12:00am
8-K
EX-5.1
ino4ccvc2xdlq hed
22 Jan 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
5:30pm